Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Erbitux

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    - PMLiVE

    Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

    The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

    - PMLiVE

    AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

    An estimated 7.2 million people in the UK are living with the progressive condition

    - PMLiVE

    NHS patients to access Theramex’s endometriosis pill following NICE recommendation

    The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

    - PMLiVE

    Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

    SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links